Home › Trials › NCT05228158

Investigating the safety of tazemetostat for patients with specific lymphoma in Japan

A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan

Observational Eisai Inc. · NCT05228158

This study is testing the safety of a drug called tazemetostat in patients with a specific type of lymphoma that has an EZH2 gene mutation to see how it works in real-life situations.

Quick facts

Study typeObservational
Enrollment145 (estimated)
SexAll
SponsorEisai Inc. Industry-sponsored
Locations232 sites (Anjo-shi, Aichi and 231 other locations)
Trial IDNCT05228158 on ClinicalTrials.gov

What this trial studies

This study focuses on assessing the safety of tazemetostat in patients who have relapsed or refractory follicular lymphoma with an EZH2 gene mutation. It is conducted in a real-world clinical setting, allowing for the observation of the drug's effects under daily practice conditions. Participants will be those who have already been treated with tazemetostat, providing insights into its safety profile in this specific patient population.

Who should consider this trial

Good fit: Ideal candidates for this study are individuals with relapsed or refractory follicular lymphoma who have an EZH2 gene mutation and have previously been treated with tazemetostat.

Not a fit: Patients who have a history of hypersensitivity to any ingredient of Tazverik will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable information on the safety of tazemetostat, potentially leading to improved treatment options for patients with this type of lymphoma.

How similar studies have performed: While this study is focused on safety, similar studies investigating tazemetostat have shown promising results in treating patients with EZH2 mutations, indicating a potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation
2. Participants treated with tazemetostat

Exclusion Criteria:

1. Participants with a history of hypersensitivity to any ingredient of Tazverik

Where this trial is running

Anjo-shi, Aichi and 231 other locations

+182 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Lymphoma, FollicularE7438TazemetostatTazverik
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.